moxifloxacin + isoniazid + rifampicin + pyrazinamide + ethambutol

This drug is a fixed-dose combination of five antibiotics—moxifloxacin, isoniazid, rifampicin, pyrazinamide, and ethambutol—used in the treatment of active tuberculosis (TB), particularly in cases where multidrug-resistant TB or specific resistance patterns are present. Each component has a distinct mechanism of action targeting Mycobacterium tuberculosis: - **Moxifloxacin** is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. - **Isoniazid** inhibits the synthesis of mycolic acids essential for the mycobacterial cell wall. - **Rifampicin** inhibits DNA-dependent RNA polymerase in bacterial cells. - **Pyrazinamide** disrupts membrane transport and energy production within M. tuberculosis under acidic conditions. - **Ethambutol** impairs cell wall synthesis by inhibiting arabinosyl transferases. This combination regimen may be used as an alternative to standard first-line therapy (HRZE) or as part of regimens for drug-resistant TB when indicated[1][3][4]. The addition of moxifloxacin can enhance bactericidal activity and help suppress resistance emergence[5]. The regimen's use should be guided by susceptibility testing and clinical guidelines.

Other names

Moxifloxacin-containing TB regimen3-month moxifloxacin regimen4-month moxifloxacin regimen